Physician profile
Dan G Guyer
NPI 1013937184
$4,546.65
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,788 · 2020: $1,265 · 2021: $494.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $602.82 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $584.86 | 2019-2021 | |
| Lundbeck LLC | $468.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $368.61 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $331.78 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $273.33 | 2019-2020 | |
| Allergan, INC. | $243.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $206.36 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.15 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $179.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.72 | 2019-2021 | |
| Shire North American Group INC | $150.30 | 2019 | |
| Ironshore Pharmaceuticals INC. | $141.98 | 2019 | |
| Abbvie INC. | $138.06 | 2021 | |
| Validus Pharmaceuticals LLC | $121.33 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $64.07 | 2019 | |
| Adlon Therapeutics L.P. | $55.31 | 2019-2021 | |
| Indivior INC. | $38.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $35.93 | 2020 | |
| Eisai INC. | $34.53 | 2020 | |
| Tris Pharma INC | $32.87 | 2019 | |
| Alfasigma USA, INC. | $21.71 | 2020 | |
| Vertical Pharmaceuticals, LLC | $20.73 | 2019 | |
| Bausch Health US, LLC | $19.52 | 2019 | |
| Acadia Pharmaceuticals INC | $17.89 | 2020 | |
| Owp Pharmaceuticals, INC. | $12.04 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Guyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.